Among other notable data from Roche at ECTRIMS ACTRIMS
are results from the extended controlled period of the Phase III ORATORIO study in primary progressive MS (PPMS), which will show the impact of OCREVUS on sustained reduction in confirmed disability progression.
Miller, PhD, opens the CMSC & ACTRIMS Cooperative Meeting with a lecture entitled: “Tolerance Directed Immunotherapies Employing Biodegradable PLG Nanoparticles - The Future of MS Treatment,” on Wednesday, May 28th.
The CMSC ACTRIMS Collaborative John Whitaker Memorial Lecture: “Role of NG2 Cells and IL-17 Signaling in EAE;” takes place on Friday, May 30th chaired by Michael Racke, MD, Suhayl Dhib-Jalbut, MD with Richard Ransohoff, MD presenting.
On the other side of the Atlantic, ACTRIMS focused on the search for biomarkers, or easy-to-read signs to diagnose MS or track the impact of treatment.
Some ACTRIMS researchers look to fields called genomics and proteomics.
On October 12, 2011, Biogen Idec announced a robust selection of data from the company's multiple sclerosis (MS) franchise were presented in 48 posters and five platform presentations during ECTRIMS and ACTRIMS
in Amsterdam, the Netherlands, October 19 through the 22.
Johnson's commitment to the link between basic research and quality clinical trials was further demonstrated when he organized ACTRIMS
(the Americas Committee for Treatment and Research in MS) to foster collaboration and cross-fertilization of ideas among laboratory scientists, researchers, and physicians who focus on patient care.
The Phase II study results presented this year during the ACTRIMS
congress showed that teriflunomide in adjunct with IFN beta significantly improved disease control (evaluated by MRI activity) beyond IFN beta plus oral placebo at one year, with a trend towards fewer clinical relapses and with a consistent safety profile with the data from a Phase II monotherapy study.
Basic and clinical MS researchers collaborate in ECTRIMS and ACTRIMS
(European--or American--Committee for Treatment and Research in Multiple Sclerosis).
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS
Further Elucidate the Anti-inflammatory Mechanism of COPAXONE[R]
The substantial amount of data presented at this year's ECTRIMS and ACTRIMS demonstrates our unwavering commitment to those living with MS and novel scientific approaches to understanding and treating the disease," said Douglas E.
Highlights of Biogen Idec's ECTRIMS and ACTRIMS Data